Effect of levofloxacin, erythromycin or rifampicin pretreatment on growth of Legionella pneumophila in human monocytes

The Journal of Antimicrobial Chemotherapy
R P SmithP Michelsen

Abstract

Opsonophagocytic killing of some bacteria (Staphylococcus aureus, Pseudomonas aeruginosa) by phagocytes is enhanced by previous brief exposure of the organism to antibiotics. We studied the regrowth of Legionella pneumophila previously pretreated with levofloxacin, erythromycin and/or rifampicin in human monocytes. The MIC for the L. pneumophila isolate of levofloxacin, erythromycin and rifampicin was 0.03, 0.5 and 0.001 mg/L, respectively. Growth of L. pneumophila from buffered charcoal yeast extract (BCYE) agar for 24 h was subcultured into BYE broth containing from 0 to 4x MIC of levofloxacin, erythromycin or rifampicin. After incubation at 35 degrees C in 5% CO2 for 18 h, the organisms were washed and opsonized with 20% heat inactivated pooled normal human serum. Thereafter, L. pneumophila was exposed to human monocytes (5:1 ratio) previously adhered to wells in tissue culture plates containing RPMI and 10% fetal calf serum. After 0, 24, 48 and 72 h of incubation, quantitative cultures of lysed human monocytes were done on BCYE agar. Our results indicate effective inhibition on L. pneumophila at 0 h regardless of the antibiotic (levofloxacin, rifampicin or erythromycin) or their concentrations (1x, 2x or 4x MIC). At 24, 48 ...Continue Reading

Citations

Jul 31, 2012·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·I Faria-RamosC Pina-Vaz
Feb 27, 2003·Antimicrobial Agents and Chemotherapy·Raymond P SmithRichard Alteri
Aug 21, 2008·Transplant Infectious Disease : an Official Journal of the Transplantation Society·C GudiolJ Carratalà
May 4, 2006·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·L Pedro-Botet, V L Yu
Nov 28, 2006·Journal of Chemotherapy·M L Pedro-BotetM Sabria
Feb 23, 2010·Infectious Disease Clinics of North America·Burke A Cunha
May 2, 2009·Expert Opinion on Pharmacotherapy·M Luisa Pedro-Botet, Victor L Yu
Jul 22, 2011·The Annals of Pharmacotherapy·Terra R VarnerHelmut Albrecht
Dec 22, 2006·Expert Review of Anti-infective Therapy·Carolina Garcia-Vidal, Jordi Carratalà
Oct 19, 2017·Brazilian Journal of Microbiology : [publication of the Brazilian Society for Microbiology]·Elif Özlem Arslan-Aydoğdu, Ayten Kimiran

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Related Papers

European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology
Joana BarbosaC Pina-Vaz
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Analia MykietiukFrancesc Gudiol
© 2021 Meta ULC. All rights reserved